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Background: Cocoa flavanols in the diet have had positive effects on cognition, blood lipid levels, 
and glucose metabolism. 
Methods: Cognitively healthy older adults aged 65–75 years were recruited for an eight-week 
randomized, double-blind controlled trial to investigate the effectiveness of cocoa flavanols on 
cognitive functions. At baseline, nutrient and polyphenol intakes from diet were assessed with 
three-day food diaries. The intervention group received 50 g dark chocolate containing 410 mg of 
flavanols per day, and the control group 50 g dark chocolate containing 86 mg of flavanols per day , 
for eight weeks. Cognition was assessed with Verbal Fluency (VF) and the Trail Making Test 
(TMT) A and B as the main outcome measures. Changes in blood lipids and glucose were also 
measured.  
Results: The older adults participating numbered 100 (63% women), mean 69 y (range 65 to 74). 
They were highly educated with a mean 14.9 years of education (SD 3.6). No differences in 
changes in cognition were seen between groups. The mean change (± SEs) in the time to complete 
the TMT A and B in the intervention group was -4.6 s (-7.1 to -2.1) and -16.1 s (-29.1 to -3.1), and 
in the controls -4.4 s (-7.0 to -1.9) and -12.5 s (-22.8 to -2.1)(TMT A p=0.93; TMT B p=0.66). No 
difference was apparent in the changes in blood lipids, glucose levels, or body weight between the 
groups.  
Conclusions: The healthy older adults showed no effect from the eight-week intake of dark 
chocolate flavanols on cognition.  
 











1. Introduction  
Diets high in polyphenols have been associated with a lower risk of cognitive decline (Lamport et 
al. 2014). Cocoa is a rich source of polyphenols, especially the flavanols epicatechin and catechin 
(Willams et al. 2012, Żyżelewicz et al. 2016). Regular consumption of cocoa flavanols may reduce 
blood pressure, improve insulin sensitivity, reduce fat oxidation, and induce vasodilation, thus 
increasing blood flow in the brain, which is essential for optimal brain function (Grassi et al. 2005, 
Grassi et al. 2008, Sorond et al. 2013, Lamport et al. 2014, Dower et al. 2015). Similarly, 
epidemiological studies show that cocoa consumption has been associated with better cognition and 
decreased Alzheimer disease (AD) risk (Commenges et al. 2000, Crichton et al. 2016). Moreover, 
flavonoid and other polyphenol-rich foods have been able to improve some cognitive domains in 
short-time trials (Nooyens et al. 2011, Kean et al. 2015, Alharbi et al. 2016, Kent et al. 2017, Miller 
et al. 2018). 
 
The antioxidant effects of flavonoids, including cocoa flavanols, were first proposed to explain their 
beneficial effects on cognitive functions (Rice-Evans et al. 2001). The main cocoa flavanol 
epicatechin can increase the bioavailability of nitric oxide, the main regulator of vascular function, 
leading to improvements in vascular tone and blood pressure regulation (Socci et al. 2017). 
Moreover, cocoa flavanols may have independent neuromodulatory and neuroprotective actions, 
and they apparently accumulate in the hippocampus, which is responsible for learning and memory 
(Sokolov et al. 2013).  
 
In recent years, an increasing amount of evidence supports the role of cocoa-derived product and 
chocolate consumption in the neurocognitive and neuroprotective enhancement of executive 
functions, attention, and memory, particularly among subjects with cognitive decline (Socci et al. 










was associated with better cognitive function, including very old people, and the relationship was 
not attenuated when adjusted for cardiovascular, lifestyle, and dietary factors (Crichton et al. 2016). 
The few intervention studies on cocoa flavanol intake and cognitive performance have shown 
mixed results. Short-term studies among healthy middle-aged or older adults showed cognitive 
benefits from cocoa flavanol consumption in cocoa drinks or supplements (Camfield et al. 2012, 
Brickman et al. 2014, Mastroiacovo et al. 2015, Neshatdoust et al. 2016 ). Similar results have been 
found for older people with high blood pressure (Sorond et al. 2013) and older people with mild 
cognitive impairment (Desideri et al. 2012), whereas one study among healthy older participants 
consuming dark chocolate together with a cocoa drink showed a null result (Crews et al. 2008). The 
trials conducted have, however, mostly been small, and the cognitive domains were measured in 
very heterogenic ways (Lamport et al. 2014). It is unknown whether the cocoa flavanol in 
commercially available dark chocolate has cognitive benefits for healthy older people.  
 
The aim of our study was to clarify the effect of an eight-week intake of commercially available 
dark chocolate with high flavanol content, especially the epicatechin content, on cognition among 
healthy older participants, 65–75-year-old men and women. The setting was a double-blind, 
randomized, controlled trial using chocolate with reduced flavanol content as a control. In addition, 












2. Subjects and methods 
 
2.1 Participants 
The participants were recruited in the capital area of Finland mainly through a public release that 
was sent to the press and radio channels. In the release the nature of the research and the main 
inclusion and exclusion criteria were described. The inclusion criteria included cognitively healthy 
adults aged 65–75 years without diagnosed, chronic diseases, whose BMI was less than 32 (in 
kg/m
2
) without a major weight change during the past year, who did not smoke, and who were 
willing to sign the informed consent. Exclusion criteria were medication for blood pressure and 
high cholesterol, current smokers, habitual users of antioxidant supplements, and daily consumers 
of chocolate or other cocoa products. Before taking any other measurements from them, the 
participants completed the SLUMS test (Tariq et al. 2006) to ensure that they had normal cognition. 
Those whose result was less than 27 points (high school education) or less than 25 (less than high 
school) were excluded.   
 
Figure 1. Recruitment of the subjects.  
 
A total of 439 subjects responded to the press release and showed interest in the study by contacting 
us by phone, email, or an internet-based registration form. Altogether 313 were excluded in the 
telephone screening, 142 due to their medical history, refusal to provide information or another 
reason for not fulfilling the inclusion criteria, and 171 respondents were excluded after the 
statistical power calculation. Based on the telephone screening, 126 persons attended the baseline 
visit, and their blood was sampled for the metabolic parameters (fP-Gluc, fS-Chol, fS-Chol-HDL, 
fS-Chol-LDL, fS-Trigly, fS-Crea, S-ALAT, S-GT, S-K, S-Na, S-Uraat). Based on the results of the 










to high total cholesterol (n=11, >7.0 mmol/l), cognitive decline (n=5), high liver value (n=4, S-
ALAT>43.0 U/l, S-GT>133.0 U/l), acute illness (n=1), and refusal (n=1). The final number in our 
study was 104 subjects, who were randomized into intervention and control groups. In both groups 
two subjects dropped out and did not give us permission to use their data. The final number of 
participants was 100 (Figure 1).  
 
The Ethics Committee of the Helsinki University Central Hospital and that of the research 
committee of the Social Insurance Institution of Finland approved the study. This trial was 
registered in ACTRN 12617000748314. 
 
2.2 Study design and outcomes 
To evaluate the effect of the daily consumption of dark chocolate on cognitive performance in 
healthy older subjects, an eight-week randomized, double-blind, parallel-arm study was conducted 
from August 2017 to December 2017. The main outcome measures were Verbal Fluency (VF) from 
CERAD (Consortium to Establish a Registry for Alzheimer’s Disease), (Morris et al. 1989) and 
Trail Making Test A and B (TMT; Lezak et al. 1998). 
At the baseline visit the participants gave blood samples, and their cognition was evaluated with the 
VF and TMT tests. A nutritionist (HSS) instructed them to keep three-day food diaries, and the 
participants received guidance on how to include dark chocolate in their daily diet and keep their 
energy intake in balance. The participants were instructed to substitute their sweet snacks with the 
reference or intervention chocolate, and they were told to limit the intake of polyphenol-rich food 
items, such as wild berries and apples, which are usually consumed in autumn time in Finland, and 
tea, red wine, fruit and vegetable juices, and chocolate other than the research chocolate. All of the 
participants received leaflets on how to follow an overall healthy and balanced diet. All of the 











Before the randomization as soon as the laboratory results were ready, the participants with an 
abnormal metabolic and cognitive profile were excluded. At the second visit, the participants 
returned their food diaries, and they were randomized into intervention and control groups. The 
participants received chocolate pralines with a white or silver paper cover on them, representing the 
blinded intervention and control groups. The pralines were divided into daily portions of 50 grams 
(seven pralines). All of the pralines for the eight-week intervention were given at the same time. 
 
The intervention group received 50 g dark chocolate per day containing 410 mg total of flavanols, 
of which 85 mg was epicatechin, and the control group received 50 g dark chocolate per day with 
86 mg total of flavanols per day, of which 26 mg was epicatechin. The intervention chocolate was 
commercially available dark chocolate (Karl Fazer 70% Dark Chocolate Pralines). The reference 
chocolate with low flavanol content was produced especially for the study purposes using higher 
processing temperatures and a longer conching time with highly processed cocoa powder. The 
intervention chocolate was higher in fibre, potassium, magnesium, and zinc and lower in sucrose 
compared to the reference chocolate. Table 1 describes the contents of the chocolates. 
 
Procyanidins were determined in Natural Resources Institute Finland (LUKE) according to Robbins 
et al. (2013). Briefly, procyanidins were extracted from defatted samples with acidified aqueous 
acetone. The extracts were purified with Strata SCX SPE (Phenomenex Inc., Torrance, CA, USA) 
cartridges and filtered into the HPLC vials. Agilent 1290 Infinity (Agilent Technologies Inc., Santa 
Clara, CA, USA) equipped with fluorescence detection (FLD; λex = 275nm, λem = 324nm) was used 
for HPLC analyses. Procyanidins were separated according to their degree of polymerization (DP) 
on a Luna Diol HILIC (Phenomenex Inc., Torrance, CA, USA) column (150 × 4.6 mm, 3 μm) at 
temperature 35 °C. The mobile phase was a binary gradient (solvents A and B) consisting of 
acetonitrile-acetic acid (98 + 2, A) and methanol-water-acetic acid (95 + 3 + 2, B). Elution was 










isocratically for 2 min and back to the starting point in 3 min. Flow rate was 1 mL/min and 
injection volume 4 μL. The post time was 5 min before next injection.  Quantification was based on 
an external standard of (-)-epicatechin (Sigma-Aldrich Inc., St Louis, MO, USA). Procyanidins with 
different DPs were quantified according to their relative response factors (in relation to (-)-










Table 1. Nutritional values of the intervention and reference chocolates. 
  
Nutrients (100 g) Reference chocolate Intervention chocolate 
Energy (kcal/kJ) 
1
 558/2336 562/2353 
Total fat (g) 
2
 35.3 40 
Saturated fatty acids (g)
 3
 21.5 24.7 
Monounsaturated fatty acids (g) 
3
 11.2 12.3 
Polyunsaturated fatty acids (g) 
3
 1 1.1 
Carbohydrates (g) 
1
 53.7 37.2 
Sucrose (g) 
4
 52.2 29.7 
Non-soluble fibre (g) 
5
 3.9 7.9 












Total flavanols (mg) 172 820 
Epicatechin (mg) 52 170 
1 Method: (EU) No 1169/2011, Eurofins Food & Feed Testing, Linköping, Sweden 
2 Method: 2009/152/EU mod., Eurofins Food & Feed Testing, Linköping, Sweden 
3 Method: Internal Method – GC-FID, GC-FID, Eurofins Food & Feed Testing, Linköping, Sweden 
4 Method: AOAC 982.14, mod., Eurofins Food & Feed Testing, Linköping, Sweden 
5 Method: Internal Method: Enzymatic-gr vimetry, Eurofins Food Testing Netherlands, 
Heerenveen, Netherlands 
6 Method: DIN EN ISO 11885, mod., Eurofins WEJ Contaminants GmbH, Hamburg, Germany 
7 Method: DIN EN ISO 17294-2-E29, mod., Eurofins WEJ Contaminants GmbH, Hamburg, 
Germany 
 
The three-day food diaries and other measurements were collected prior to randomization. The 












The baseline measurements included demographic data, diagnoses, and medication. The diagnoses 
and medications were confirmed based on written medical records and prescriptions provided by 
the participants. We also assessed the participants’ cognition with the Saint Louis University Mental 
Status (SLUMS) Exam (Tariq et al. 2006) to confirm the subjects’ capability of participating in the 
intervention.  
At baseline and follow-up, we measured the participants’ weight and height and calculated their 
body mass index (BMI). We measured weight with a portable and calibrated scale, and height with 




The Trail Making Test (TMT) A and B (Lezak et al. 1998) and Verbal Fluency (VF) (Morris et al. 
1989) were used to assess the change in cognition during the intervention. The TMT is a 
neuropsychological test of visual attention and task switching. It consists of two parts in which the 
subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining 
accuracy. A lower number of seconds indicates better performance. The test can provide 
information about mental flexibility, processing speed, and executive functioning. In the VF test, 
the participant produces as many animal words as possible in 60 seconds. A higher number of 
animals indicates better performance. A good performance in VF indicates mental flexibility and 
cognitive productivity (Sotaniemi et al. 2012). 
 
We used the three-day food diaries to assess food and nutrient intake. During the first visit the 
nutritionist gave written and verbal instructions to the participants on how to keep the food diaries. 
She also gave the participants 100 mL, 15 mL, and 5 mL measuring cups for measuring food items 
such as drinks and bread spreads. The participants were instructed to complete the food diaries over 
a period of three days including one weekend day while maintaining their usual diet. Participants 










checked by the nutritionist were the types of milk and fat used, and the trademarks of the food items 
or the amounts of food. Energy, protein, and nutrient intake were calculated using the AIVO-diet 
nutrition program (https://www.mashie.com/fi/palvelut/ravintolaskenta/). 
 
Blood samples were drawn from the participants after an overnight fasting period at the beginning 
and the end of the trial. We used a laboratory package to ensure that the participants’ health 
condition was stable and adequate for this intervention. The participants’ fasting plasma glucose, 
cholesterols (total, HDL, and LDL), triglycerides, haemoglobin (B-Hb, E-MCHC, E-MCH), 
erythrocytes (B-HKR, E-MCV), leucocytes, platelets, creatinine, alanine aminotransferase, and 
glutamyl transferase were determined. In addition, we wanted to explore whether the intervention 
had an effect on the laboratory values.  
 
2.4 Sample size 
Sample size calculation was based on the Trail Making Test (TMT A). It was assumed that a 
minimum group difference would be 20% in the points of the TMT A with a type I error of 5%, 
statistical power of 80%, and 20% of drop outs in the groups, which resulted in 50 participants per 
group (Mastroiacovo et al. 2015). 
 
2.5 Randomization  
The participants who met all the inclusion criteria and had sufficient cognitive performance (n = 
104) were randomly allocated to the intervention (n = 52) and control (n = 52) groups according to 
a computer-generated randomization list.  Four participants dropped out and refused permission to 












The intervention was double-blinded. Neither the researchers nor participants were aware of the 
treatment allocation. The chocolate pralines were wrapped with a white or silver paper cover 
representing the blinded intervention and control groups. The code was revealed after the 
intervention was finished.  
 
2.7 Statistical methods 
Data are presented as means with standard deviation (SD) or as counts (n) with percentages (%). 
Statistical comparison between the groups was performed by t-test. The method (achieved 
significance level) was used when the theoretical distribution of the test statistics was unknown or 
in the case of a violation of the assumptions (e.g. non-normality). Effect size (d) for the intervention 
was calculated by using Cohen’s method where an effect size of 0.20 is considered small, 0.50 
moderate, and 0.80 large. CIs for the effect sizes were obtained by bias-corrected bootstrapping 
(5000 replications).  The normality of the variables was tested by using the Shapiro-Wilk W test. 




3.1 Baseline  
The number of participants was 100 (63% women), and their mean age was 69 years (SD 2.5). The 
mean BMI of the participants in the whole group was 25.0 kg/m
2
 (SD 3.6). They had a mean 
education of 14.9 years (SD 3.6), and their HRQoL was good. The mean level of blood glucose was 










The groups were similar at baseline. The baseline characteristics in the intervention and reference 














Table 2. Background characteristics, lifestyle factors, and metabolic and cognitive parameters 
at baseline. 







Women, n (%) 30 (60) 31 (62) 
Age, mean (SD) 68 (3) 69 (2) 
Years of education, mean (SD) 14.9 (3.8) 14.4 (3.0) 
Cohabiting, n (%) 27 (54) 29 (58) 
SLUMS, mean (SD) 27.8 (1.4) 28.0 (1.2) 
Dietary intake, mean (SD)   
Energy (kJ) 7564 (1650) 8228 (2109) 
Energy (kcal) 1807 (394) 196 5(504) 
Total fat (g) 79.9 (26.2) 89.0 (33.3) 
Saturated fat (g) 28.2(10.7) 31.9 (14.3) 
Protein (g) 72.9 (20.9) 81.5 (25.3) 
Carbohydrates (g) 221 (49) 232 (61) 
Sucrose (g) 84.9 (28.2) 85.2 (30.0) 
Fibre (g) 23.4 (8.1) 24.7 (10.4) 
Salt (mg) 7310 (2914) 7418 (2343) 
Vitamin D (µg) 8.89 (4.95) 9.76 (6.80) 
Folate (µg) 276 (138) 287 (100) 
Potassium (mg) 3741 (875) 3787 (1105) 
Calcium (mg) 978 (332) 1024 (386) 
Clinical parameters, mean (SD)   
   BMI (kg/m
2
) 24.3 (3.6) 25.4 (3.5) 
   Waist circumference (cm)   
      Women 83 (11) 86 (11) 
      Men 94 (8) 96 (9) 
   GDS 1.8 (3.0) 2.3 (3.6) 
Laboratory parameters, mean (SD)   
   Fasting plasma glucose (mmol/L) 4.93 (0.29) 5.00 (0.45) 
   Total cholesterol (mmol/L) 5.60 (0.74) 5.66 (0.63) 
   LDL cholesterol (mmol/L) 3.42 (0.56) 3.37 (0.55) 
   HDL cholesterol (mmol/L) 1.73 (0.44) 1.84 (0.47) 





In the intervention group the participants ate 94% of the offered chocolate, whereas in the control 











No differences were seen in changes in cognition between groups. The mean change (95% CI) in 
the time to complete TMT A and B in the intervention group was -4.6 s (-7.1 to -2.1) and -16.1 s (-
29.1 to-3.1), and in the controls -4.4 s (-7.0 to -1.9) and -12.5 s (-22.8 to -2.1)(Table 3). 
 
 
Table 3. Changes in cognitive parameters during the intervention.  
 













Mean (95% CI) 
Intervention 
N=50 
Mean (95% CI) 
  
Trail Making Test, s        
   A 41.0 
(10.4) 
41.1 (10.3)  -4.4 (-7.0 to -
1.9) 
-4.6 (-7.1 to -
2.1) 
0.93 0.02 (-0.37 to 
0.41) 
   B  91.1 
(41.8) 
95.3 (44.4)  -12.5 (-22.8 to -
2.1) 
-16.1 (-29.1 to -
3.1) 
0.66 0.09 (-0.31 to 
0.48) 
Verbal Fluency test, 
words/60 s 
23.0 (4.9) 23.6 (5.5)  2.8 (1.4 to 4.3) 3.0 (1.6 to 4.3) 0.90 0.02 (-0.37 to 
0.42) 
SLUMS 27.8 (1.4) 28.0 (1.2)  1.1 (0.6 to 1.6) 1.3 (0.8 to 1.6) 0.59 0.11 ( -0.29 to 
0.50) 
Cerad 14.2 (1.1) 13.8 (1.0)  0.3 (0.1 to 0.6) 0.5 (0.2 to 0.8) 0.35 0.19 (0.21 to -
0.58) 
*Effect size (d) was calculated by using the Cohen’s method where an effect size of 0.20 is considered small, 0.50 




No differences were seen in the changes of metabolic parameters during the intervention between 
the intervention and control groups (Table 4.).  
Table 4. Changes in metabolic parameters during the intervention. 
 
 
















Weigth, Kg 70.0 (12.9) 73.4 (12.3)  0.6 (0.3 to 0.9) 0.3 (0.0 to 
0.7) 
0.20 
Fasting plasma glucose 
(mmol/L) 















































Daily consumption of 50 grams of dark chocolate with high flavanol content for eight weeks did not 
influence the cognitive parameters that were studied among healthy participants aged 65–75 years 
in this double-blind, placebo-controlled, randomized trial. In addition, no differences were seen in 
the changes in the intervention and control participants’ weight or blood glucose and lipid levels. 
The compliance with the chocolate intake was excellent in both groups. This is one of the few 
randomized double-blind controlled trials studying the effects of dark chocolate that is naturally 
high in cocoa flavanols on the cognitive functions of cognitively healthy older people.  
 
The heterogeneity of a study design that studies the effects of cocoa flavanols on cognitive 
functions is a major challenge. Yet only a few trials have examined the effects of cocoa flavanol 
intake on cognitive functions in middle-aged or older adults (Crews et al. 2008, Camfield et al. 
2012, Desideri et al.2012, Sorond et al. 2013, Brickman et al. 2014, Mastroiacovo et al. 2015, 
Neshatdoust et al. 2016).  In addition to our study, Crews et al. (2008) is the only trial investigating 
the effects of dark chocolate naturally high in cocoa flavanols on cognitive functions. Crews et al. 
(2008) studied the effects of 60% dark chocolate bars (37 g, 397 mg flavanols) and cocoa beverage 
(237 ml, 357 mg flavanols) on neuropsychologic functions and cardiovascular health among healthy 
subjects over 60 years of age in a six-week intervention. Our results are in line with their findings, 










cognitive functions or cardiovascular health. The amount of cocoa flavanols in the study by Crews 
et al. (2008) was almost double compared to the dose in our trial (410 mg/50 g daily dose of dark 
chocolate).  
 
In most trials, cocoa flavanols have been consumed as drinks (Desideri et al. 2012, Sorond et al. 
2013, Mastroiacovo et al. 2015, Neshatdoust et al. 2016) or as part of a diet that includes 
supplements (Brickman et al. 2014), and only one previous study included a dark chocolate bar in 
addition to a cocoa drink (Crews et al. 2008). The intervention chocolate in this trial was 
commercially available dark chocolate naturally high in cocoa flavanols (410 mg/daily portion), 
which is close to the daily dose (494–520 mg) that has been proven effective in previous trials 
(Desideri et al. 2012, Mastroiacovo et al. 2015, Neshatdoust et al. 2016).  The type and 
bioavailability of cocoa flavanols may differ in enriched products such as drinks (Desideri et al. 
2012, Sorond et al. 2013. Mastroiacovo et al. 2015, Neshatdoust et al. 2016) and supplements 
(Brickman et al. 2014) compared to dark chocolate naturally high in cocoa flavanols (Crews et al. 
2008), which may have affected the results. Further studies should compare the neurocognitive 
effects of different types of products co taining cocoa flavanols.   
 
In previous trials, the participants’ age, health and cognitive status, and educational level have been 
heterogeneous. A few trials have included healthy middle-aged and older adults (Camfield et al. 
2102, Brickman et al. 2014, Mastroiacovo et al. 2015, Neshatdoust et al. 2016), another studied 
subjects with mild cognitive impairment (Desideri et al. 2012), and one study examined participants 
with vascular risk factors (Sorond et al. 2013). Our participants were 65–75 years of age, and at this 
age the decline in cognitive performance begins to show in tests. However, the participants in this 
study had a healthy cognitive status and metabolic profile compared to the population of the same 










baseline met the recommendations well (Valsta et al. 2018, FinDiet 2017 Study). In addition, the 
education level of the subjects was high with a mean over 14 years of education, and at baseline 
they performed cognitive tests with excellent results. Higher educational levels compared with 
lower levels have been associated with a greater cognitive reserve and result in better performance 
in cognitive tests (Lezak et al. 2004). These facts may have caused a ceiling effect on the cognition 
outcome parameters.  
 
Some previous studies in different age groups have shown favourable effects of cocoa flavanols on 
the parameters of cardiovascular health such as LDL- and HDL-cholesterol levels, flow-mediated 
dilatation, and insulin resistance; however, the results are conflicting (Hooper et al. 2012). The 
latest trials with a higher cocoa flavanol dose in drinks com ared to the dose in dark chocolate in 
our trial have shown positive effects on metabolic profile (Desideri et al. 2012. Mastroiacovo et al. 
2015). In our trial, we did not find any differences in weight, lipid profile, or fasting glucose levels 
between the baseline and end of the intervention, suggesting that dark chocolate is a safe source of 
cocoa flavanols for healthy older adults.  
 
We chose the Trail Making Test (TMT) and Verbal Flow test as the main outcome measures based 
on the latest scientific knowledge (Morris et al. 1989, Lezak et al. 1998) because the combination of 
these tests is feasible for this kind of trial and the most sensitive for measuring changes in 
intervention among older adults (Lezak et al. 2004). The same cognitive measurements have also 
been used in previous trials (Desideri et al. 2012, Sorond et al. 2013, Mastroiacovo et al. 2015). The 
cognitive tests have evaluated the indirect association between cocoa flavanol intake and cognitive 
performance but do not provide information on the direct mechanisms of action of cocoa flavanols. 
Two potential explanations are improvements in the cerebral blood volume or an increase in serum 










2016). A recent meta-analysis found that patients with Alzheimer’s disease, but not mild cognitive 
impairment, have significantly lower serum BDNF levels compared to healthy controls (Ng et al. 
2019). Future research should include modern neuroimaging techniques that enable measuring the 
changes in neuromodulatory properties such as brain signalling activity, neurogenesis, and blood 
flow (Sokolov et al. 2013). Functional near infrared spectroscopy (fNIRS) is a novel method which 
measures the cortical blood flow or hemodynamics (Ho CS et al 2016). fNIRS can be used to assess 
cognitive impairment and neuropsychiatric disorder (Ho CS et al 2018). As depression was found to 
be associated with cardiovascular risk factors (Ho RC et al 2018) and regular consumption of cocoa 
flavanols may reduce cardiovascular risk factors. Further research is required to assess the potential 
benefits on hemodynamics and depression in older adults (Husain et al 2019).  
 
The strength of our study is the study design of a randomized, double-blind, and controlled trial 
using commercially available dark chocolate naturally high in cocoa flavanols and dark chocolate 
with low flavanol content as a reference. The recruitment process was very fluent due to the high 
interest in an intervention concerning chocolate. The compliance with consuming the daily dark 
chocolate portion was high, and the drop-out level was very low. The limitations of our study are 
the small sample size and high educational level and cognitive status compared to the average in the 
same age group. Thus, the cognitive outcomes may have had a ceiling effect. The participants might 
have been a selected group of people that are especially interested in their health and nutrition.   
5. Conclusions  
In conclusion, the short-term use of dark chocolate naturally high in flavanols showed no benefit in 
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 Only few trials have studied how dark chocolate affects cognition in older adults.  
 Short-term dark chocolate consumption did not show beneficial effects on cognition.   
 Dark chocolate is a safe source of cocoa flavanols for healthy older adults.  
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